Bharat Biotech-Brazil row: Covaxin nod under controlled conditions

The agency said the suspension - which put the EUA application on ice - was due to missing data from the vaccine's clinical trials

As controversy over the $324-million deal for 20 million doses of Covaxin with Brazil brews, on Monday some reports pointed out that the Brazilian regulator had not granted Bharat Biotech — the makers of Covaxin — emergency-use authorisation (EUA).

The Hyderabad-based company’s website noted that on June 4, ANVISA — the Brazilian regulator — had authorised the “exceptional import of Covaxin by the health ministry for distribution and use under controlled conditions”.

This is a departure from the June 30 press statement wherein the company had clarified it had not received any money from Brazil’s health ministry.

On Monday, NDTV reported that ANVISA